Tefinostat

Drug Profile

Tefinostat

Alternative Names: CHR-2845; Tefinostat tartrate

Latest Information Update: 01 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chroma Therapeutics
  • Developer Cardiff University; Chroma Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic myelomonocytic leukaemia
  • Phase I/II Inflammation
  • No development reported Haematological malignancies; Lymphoma

Most Recent Events

  • 24 Sep 2015 Phase-II clinical trials in Chronic myelomonocytic leukaemia in United Kingdom (PO) (ISRCTN17394489)
  • 17 Sep 2015 No recent reports on development identified - Phase-I for Haematological malignancies and Lymphoma in Belgium, France, Netherlands (PO)
  • 05 Mar 2015 Tefinostat is still in phase I/II trials for Inflammation (associated with cancer in patients with hepatocellular carcinoma) in United Kingdom
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top